Neurocrine (NBIX) HR chief sells 36,937 shares and exercises options in pre-set plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Neurocrine Biosciences’ Chief Human Resources Officer Julie Cooke reported a mix of option exercise and share sales in company common stock. On June 2, 2026, she exercised 24,965 non-qualified stock options at an exercise price of $81.49 per share, converting them into common shares. The filing shows her holding 59,311 common shares directly after this exercise.
That same day, she executed a series of open-market sales totaling 36,937 common shares at weighted average prices ranging from the mid‑$154 to high‑$158 area, with specific ranges from $154.20 to $158.91. A footnote states these dispositions were carried out by a broker under a pre‑arranged Rule 10b5‑1 trading plan adopted on March 3, 2026. The filing also notes that 20,334 of the reported shares are held by the Cooke Family Trust of 2004, over which Cooke has voting and investment power.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 36,937 shares ($5,770,235)
Net Sell
7 txns
Insider
Cooke Julie
Role
Chief Human Resources Officer
Sold
36,937 shs ($5.77M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option | 24,965 | $0.00 | -- |
| Exercise | Common Stock | 24,965 | $81.49 | $2.03M |
| Sale | Common Stock | 14,214 | $154.8252 | $2.20M |
| Sale | Common Stock | 5,466 | $155.4566 | $850K |
| Sale | Common Stock | 4,216 | $156.766 | $661K |
| Sale | Common Stock | 9,521 | $157.6161 | $1.50M |
| Sale | Common Stock | 3,520 | $158.5897 | $558K |
Holdings After Transaction:
Non-Qualified Stock Option — 0 shares (Direct, null);
Common Stock — 59,311 shares (Direct, null)
Footnotes (1)
- Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $154.20 to $155.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.20 to $156.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $156.26 to $157.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.26 to $158.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $158.26 to $158.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. 20,334 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.
Key Figures
Shares sold: 36,937 shares
Options exercised: 24,965 shares
Option exercise price: $81.49/share
+3 more
6 metrics
Shares sold
36,937 shares
Total common shares sold on June 2, 2026 in open-market trades
Options exercised
24,965 shares
Non-qualified stock options converted to common stock on June 2, 2026
Option exercise price
$81.49/share
Exercise price for non-qualified stock options granted February 5, 2018
Post-exercise holdings
59,311 shares
Common shares held directly after option exercise transaction
Sale price range
$154.20–$158.91
Weighted average sale price ranges for common stock sales
Trust-held shares
20,334 shares
Shares held by the Cooke Family Trust of 2004 with voting and investment power
Key Terms
Rule 10b5-1 trading plan, Non-Qualified Stock Option, weighted average sales price, Employee Stock Purchase Plan, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option financial
"security_title": "Non-Qualified Stock Option""
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
weighted average sales price financial
"Represents a weighted average sales price per share. These shares were sold in multiple transactions"
Employee Stock Purchase Plan financial
"shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
vesting financial
"The option was granted February 5, 2018 and vested in 48 equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transactions did NBIX executive Julie Cooke report on this Form 4?
Julie Cooke reported exercising non-qualified stock options and selling common shares. She exercised 24,965 options at $81.49 per share and sold 36,937 Neurocrine Biosciences common shares in open-market transactions on June 2, 2026, at weighted average prices in the mid-$150s.
At what price did Julie Cooke exercise her NBIX stock options?
She exercised 24,965 non-qualified stock options at an exercise price of $81.49 per share. These options, granted on February 5, 2018, had vested in 48 equal monthly installments beginning March 5, 2018, according to the disclosed vesting schedule.